Home NDC 63629-5014 Lamivudine
Product NDC 63629-5014
11-digit product format 636295014
Labeler code 63629
Product ID 63629-5014_604a8e53-939c-4df7-8a43-069c5d3eca89
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name Lamivudine
Dosage form TABLET, FILM COATED
Route ORAL
Labeler Bryant Ranch Prepack
Application ANDA202032
Marketing category ANDA
Marketing start 2011-11-17
Marketing end 0000-00-00
Substance LAMIVUDINE
Active strength 150 mg/1
Pharmacologic classes Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
NDC exclude flag E
Listing certified through 2017-12-31
Current FDA listing Historical FDA.report record
Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 36 matching rows.
View current auxiliary records. · View the auxiliary file history.
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date A202032-001 LAMIVUDINE LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 A202032-002 LAMIVUDINE LAMIVUDINE 300MG TABLET / ORAL 2011-11-17
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 3 · 88 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-10-15 13:18:30 2026-09 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 c2088c7a36db…2026-10-15 13:18:30 2026-09 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 c2088c7a36db…2026-09-14 22:38:34 2026-08 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 84e616aacf4f…2026-09-14 22:38:34 2026-08 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 84e616aacf4f…2026-08-18 06:07:40 2026-07 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 caaa826d4ba7…2026-08-18 06:07:40 2026-07 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 d06236e962d9…2024-10-29 15:01 UTC 2024-10 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 8072bd15b7f6…2024-05-31 18:47 UTC 2024-05 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 5c6f7cd8ea54…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 A202032-001 LAMIVUDINE 150MG TABLET / ORAL 2011-11-17 5d02ea3f76ae…2022-04-08 23:34 UTC 2022-04 A202032-002 LAMIVUDINE 300MG TABLET / ORAL 2011-11-17 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 A202032-001 LAMIVUDINE 150MG TABLET / ORAL AB 2011-11-17 4b0b4de00fa7…2022-04-04 05:41 UTC 2022-04 A202032-002 LAMIVUDINE 300MG TABLET / ORAL AB 2011-11-17 4b0b4de00fa7…
Observed Orange Book normalized TE history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.